EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides

Annemieke Aartsma-Rus iD, Alejandro Garanto iD, Willeke van Roon-Mom iD, Erin M McConnell, Victoria Suslovitch, Winston X Yan, Jonathan K Watts, Timothy W Yu

Nucleic Acid Therapeutics · 01.02.2023 · 33 (1) · 17-25

DOI: 10.1089/nat.2022.0060 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 13.12.2022. Verfasst von Annemieke Aartsma-Rus und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Center for RNA Therapeutics, the Netherlands. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, RNA Splicing. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antisense oligonucleotides (ASOs) can modulate pre-mRNA splicing. This offers therapeutic opportunities for numerous genetic diseases, often in a mutation-specific and sometimes even individual-specific manner. Developing therapeutic ASOs for as few as even a single patient has been shown feasible with the development of Milasen for an individual with Batten disease. Efforts to develop individualized ASOs for patients with different genetic diseases are ongoing globally. The N = 1 Collaborative (N1C) is an umbrella organization dedicated to supporting the nascent field of individualized medicine. N1C recently organized a workshop to discuss and advance standards for the rigorous design and testing of splice-switching ASOs. In this study, we present guidelines resulting from that meeting and the key recommendations: (1) dissemination of standardized experimental designs, (2) use of standardized reference ASOs, and (3) a commitment to data sharing and exchange.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseRNA SplicingHumansExonsPrecision Medicine

Stichwörter der Autor:innen

N-of-1antisense oligonucleotideexon skippingprotocol

Substanzen

Oligonucleotides, Antisense

Autor:innen und Institutionen

  • Dutch Center for RNA Therapeutics, the Netherlands.
  • Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • N = 1 Collaborative.
  • Department of Pediatrics and Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.
  • RNA Therapeutics Institute, UMass Chan Medical School, Worcester, Massachusetts, USA.

ORCID-Profile: Annemieke Aartsma-Rus, Alejandro Garanto, Willeke van Roon-Mom

Förderung

  • NICHD NIH HHS

Zitieren

APA

Aartsma-Rus, A., Garanto, A., van Roon-Mom, W., McConnell, E. M., Suslovitch, V., Yan, W. X., Watts, J. K., & Yu, T. W. (2023). Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic Acid Therapeutics, 33(1), 17-25. https://doi.org/10.1089/nat.2022.0060

Vancouver

Aartsma-Rus A, Garanto A, van Roon-Mom W, McConnell EM, Suslovitch V, Yan WX, et al. Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic Acid Therapeutics. 2023;33(1):17-25. doi:10.1089/nat.2022.0060

BibTeX
@article{AartsmaRus2023,
  author = {Aartsma-Rus, Annemieke and Garanto, Alejandro and van Roon-Mom, Willeke and McConnell, Erin M and Suslovitch, Victoria and Yan, Winston X and Watts, Jonathan K and Yu, Timothy W},
  title = {Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides},
  journal = {Nucleic Acid Therapeutics},
  year = {2023},
  volume = {33},
  number = {1},
  pages = {17--25},
  doi = {10.1089/nat.2022.0060}
}
Kostenlos starten →